Standing Order
Vertex Pharmaceuticals Incorporated

Dashboard

Vertex Pharmaceuticals Incorporated

VRTXNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$121B
Price$477.3652w $366.54 – $529.59
Conviction5/ 5
Revenue (TTM)$12.3B
Revenue growth YoY+10.4%
P/E (trailing)27.9
Gross margin86.3%
Operating margin39.0%
Net margin35.4%
52w price change+7.2%
Next earningsAug 3, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Jul 23
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 23
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 21
    OtherClinicalTrials.gov

    Vertex updates NCT06747572 (PKD1 gene variants in ADPKD) to ACTIVE_NOT_RECRUITING status

  • Jul 21
    OtherClinicalTrials.gov

    Vertex Phase 3 trial NCT05444257 (VX-121 combo) status updated to ACTIVE_NOT_RECRUITING

  • Jul 21
    Trial initiationClinicalTrials.gov

    Phase 2 trial (NCT07501702) of povetacicept in generalized myasthenia gravis recruiting, sponsored by Vertex.

  • Jul 21
    Trial readoutClinicalTrials.gov

    Phase 3 trial NCT05331183 (ELX/TEZ/IVA long-term safety/efficacy, non-F508del) status updated to ACTIVE_NOT_RECRUITING.

  • Jul 20
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07231419 recruiting for suzetrigine in diabetic peripheral neuropathy pain (Vertex sponsor).

  • Jul 20
    Trial initiationClinicalTrials.gov

    Vertex initiates Phase 2/3 trial (NCT07204275) of povetacicept in primary membranous nephropathy; status recruiting.

  • Jul 17
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 17
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 16
    Trial initiationClinicalTrials.gov

    Vertex initiates Phase 1 dose-escalation study (NCT07283770) of VX-581 in healthy participants; status recruiting.

  • Jul 7
    OtherSEC

    8-K filing (items 1.01, 7.01, 8.01, 9.01) on entry into material definitive agreement and related disclosures.

  • Jul 7
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 7
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jul 6
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 1
    Trial initiationClinicalTrials.gov

    Vertex updates NCT05356195 phase 3 trial of CTX001 in pediatric TDT; status ACTIVE_NOT_RECRUITING as of 2026-07-01.

  • Jul 1
    OtherClinicalTrials.gov

    Phase 3 trial NCT05329649 (CTX001 pediatric SCD) status updated to ACTIVE_NOT_RECRUITING

  • Jun 30
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 30
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT04786262 of VX-880 in Type 1 diabetes updated to RECRUITING status

  • Jun 30
    Trial initiationClinicalTrials.gov

    Vertex starts Phase 2 long-term safety/efficacy study of VX-670 in Myotonic Dystrophy Type I (NCT06926621, enrolling by invitation).

Not financial advice — research and opinion only. Disclosures